Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA193
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

February 2014: implementation section updated to clarify that rituximab is recommended as an option for treating relapsed or refractory chronic lymphocytic leukaemia. Additional minor maintenance update also carried out.

March 2012: minor maintenance

ISBN: 978-1-4731-5668-5

  • National Institute for Health and Care Excellence (NICE)